ARTIVION, INC. (AORT) stock intrinsic value fair value estimate & owner earnings analysis

Artivion makes devices and services for aortic and heart surgery. 2025 revenue was $441.3 million, up 14%: aortic stent grafts about 36% of sales (up 29%, sold mostly outside the US), On-X mechanical heart valves $101.7 million (up 21%), BioGlue surgical sealants $76.6 million (up 4%) and cardiac and vascular tissue preservation services $95.5 million (down 3%). North America produced $221.7 million of sales, Europe/Middle East/Africa $151.4 million and Asia Pacific $44.3 million. In the first half of 2026 revenue rose 14% to $242.1 million at a gross margin of about 64%, but the company still posted an operating loss of $2.6 million. How we measure cash. We start with operating cash flow, remove the cash absorbed by growing receivables, inventory and prepaid items (between $10 million and $33 million every year from 2017 to 2025), then charge stock compensation ($24.4 million in 2025, up from $14.2 million) and maintenance capital spending ($17.0 million in 2025). A one-off $20.3 million purchase of Austin, Texas buildings in December 2025 (two had been leased) is left out as not maintenance. We then add back interest paid, because lenders are valued separately. That cash before lenders was $22.7 million (2021), $12.5 million (2022), $32.7 million (2023), $39.7 million (2024) and $48.9 million (2025). We start from the five-year median, $32.7 million, and deduct $4.5 million a year for the recurring write-off of unusable tissue and inventory ($4.9 million in 2025, $4.4 million in 2024, $4.8 million in 2023), a real cost that the working-capital adjustment would otherwise hide. The starting level is $28.2 million. We did not use 2025's $48.9 million because the first half of 2026 shows no cash improvement despite 14% sales growth: operating cash flow was -$0.1 million versus -$1.9 million a year earlier, capital spending $18.8 million versus $6.9 million, and stock compensation $16.6 million versus $14.2 million. We could not determine from the figures available what the larger 2026 capital spending is for. Using only 2023 to 2025 would lift the starting point to about $35 million and the base value to roughly $5 a share; this is the largest judgement in the analysis. What the company owes. At June 30, 2026: $370 million of senior secured, interest-only loans from Ares-managed funds, floating rate (8.74% on the term loans at year-end 2025), all due January 18, 2031; $77.3 million of cash, of which we treat $25 million as needed to run the business; and $96.5 million of recorded contingent payments, which include up to $100 million of milestone payments to former Ascyrus shareholders. The half-year accounts show $116.7 million paid to acquire a business and $152.9 million of new borrowing, consistent with taking up the option to buy Endospan, maker of the NEXUS arch stent graft, which the annual report priced at $135 million upfront (including loan offset) plus earn-outs of up to $200 million. We could see only the tagged figures of the half-year report, not its text, so we could not confirm those terms. We also could not estimate Endospan's operating costs: it was not consolidated in the historical figures, so those costs are not in any case. Because the loans cost about 8.7%, roughly 2.7 percentage points above a 6% benchmark, for the 4.5 years to 2031, we add $39 million. Total claims ahead of shareholders: about $454 million, or $9.35 per share on 48.5 million diluted shares. Annual interest is about $32 million. Base case: worth $567 million, owes $454 million, leaving $114 million, or $2.34 a share. Cash before lenders grows 3% a year for five years, 2% for three and 1% for two, reaching about $35 million, then holds flat. Cash before lenders grew 23% in 2025; year one here assumes 3%, so no reversal of a slowdown is needed. The growth credited is the kind the older lines have shown: BioGlue grew 4% in 2025 led by price, and revenue has risen in nine of the last ten years (only 2020 fell, by 8%). Left out because none has happened yet: US approval of AMDS (the company expects it in 2026), NEXUS, further share gains in stent grafts and On-X, and margin expansion. Even 2025's $52.8 million revenue gain absorbed $22.2 million of working capital, which is why credited growth is small. Holding the level flat after year ten rests on that record; BioGlue is described as a mature product with expired patents, so this is a judgement. In the early years base cash before lenders ($29 to $32 million) only roughly covers interest; the excess cash covers the gap. Bear case: worth $385 million, owes $454 million, short by about $68 million, or -$1.41 a share: the company appears to owe more than the business is worth. It repeats the company's own record after the 2020 revenue decline (revenue fell 8% to $253.2 million, with falls in every product except PhotoFix), when cash before lenders went from $37.9 million (2020) to $22.7 million (2021) and $12.5 million (2022) before recovering to $32.7 million (2023). Applied to today's $28.2 million that gives $16.9 million, $9.3 million, then $24.3 million for good. With cash before lenders well under the $32 million interest bill, lenders would be unlikely to leave this structure in place, and we assume shareholders keep nothing. Bull case: worth $1,040 million, owes $454 million, leaving $586 million, or $12.09 a share. Cash before lenders holds at 2025's level less write-offs ($44.4 million) and grows 6% a year for five years, 3% for three and 1% for two, below the roughly 12% revenue pace of the last three years. No new products or approvals are included. Margin-of-safety price judgement. We are only moderately sure of the level: it has been positive every year but ranged from $12.5 million to $48.9 million over the last five, and because shareholders own the small remainder after $454 million of claims, each $1 million of lasting annual cash before lenders is worth about 40 cents a share. The worst plausible outcome is the bear case plus costs we cannot size: Endospan's spending if NEXUS approval slips, and a 2031 refinancing at higher rates with floating-rate debt that already absorbs most of the cash; in that outcome the equity is worth nothing. Our most likely errors are the starting level (cash of about $17 million, like 2021-22, puts the shares below zero; the 2023-25 window puts them near $5), stock compensation (the first-half 2026 pace annualizes near $33 million, which would cost roughly $3.60 a share if it persists), and the contingent payments (if milestone payments are never earned, claims fall by roughly $1.25 to $2 a share). The company discontinued its dividend in December 2015 and its credit facility restricts payments, so the whole return must come from value building over about five years to the 2031 maturity. At $0.90 the shares would need to reach about $2.25 in five years for a 20% annual return, which holds if cash before lenders settles at about $27 million or better and the debt is refinanced on similar terms. That is the basis for the margin-of-safety price of $0.90. Earlier estimates were built on a different basis and are not comparable.